Effectiveness of Anti-Obesity Drugs for CVD Prevention: A Clinician Discussion

Novel Oral Antiobesity Drug Shown to Reduce Body Weight by up to 13% in First-In-Human Study

Commentary

Video

For patients with obesity, prevention efforts to reduce the risk of cardiovascular disease (CVD) include both lifestyle interventions (eg, healthy diet, regular exercise) and medications, such as statins and glucagon-like peptide-1 (GLP-1) analogs. GLP-1 analogs, such as semaglutide and the dual incretin agonist tirzepatide were originally indicated for type 2 diabetes management and have recently been approved for weight loss in patients with obesity. How can these medications aid in treating CVD in patients with obesity? Anila Chadha, MD, family physician and obesity medicine physician at Dignity Health Medical Group in Bakersfield, California, discusses this topic and more in the video above.

For part 1 of our interview with Dr Chadha, please click here.

Related Content

September 18th 2024

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.

August 30th 2023

Good Cardiovascular Health Early on May Offset Genetic Risk of Hypertensive Disorders of Pregnancy

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

September 17th 2024

Obesity & Type 2 Diabetes: An Expert Discussion

New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.

June 30th 2023

Awareness of Uncontrolled Hypertension Low, Particularly Among Young Adults, Study Warns

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Uncontrolled Hypertension Awareness is Low in the US / image credit blood pressure concept: ©H_Ko/stock.adobe.com

Grace Halsey

Atrial Fibrillation in the US 3-Fold More Prevalent Than Previously Estimated, New Data Suggest

Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.

Rose McNulty

Novel Oral Antiobesity Drug Shown to Reduce Body Weight by up to 13% in First-In-Human Study

Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.

Related Content

September 18th 2024

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.

August 30th 2023

Good Cardiovascular Health Early on May Offset Genetic Risk of Hypertensive Disorders of Pregnancy

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

September 17th 2024

Obesity & Type 2 Diabetes: An Expert Discussion

New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.

June 30th 2023

Awareness of Uncontrolled Hypertension Low, Particularly Among Young Adults, Study Warns

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Grace Halsey

Atrial Fibrillation in the US 3-Fold More Prevalent Than Previously Estimated, New Data Suggest

Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.

Rose McNulty